Tenaya, With $92m Financing, Aims To Win In Cardiology With Three Platforms

Tenaya is working on three separate approaches (gene therapy, cell therapy and small molecule) to develop new treatments for heart disease.

rows of coins and blurred bokeh for finance and banking concept - Image
Tenaya's three-pronged approach to heart disease led to $92m series B. • Source: Shutterstock

South San Francisco startup Tenaya Therapeutics Inc. has ambitious plans to advance three drug development platforms for cardiovascular disease: cell therapy, gene therapy and small molecule precision medicine. After completing a rich series B round, which drew $92m in financing, the company says it has sufficient funding to move all three platforms toward the clinic.

"The $92m raise, it was large partly because we excited many investors who saw the potential of not one, not...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Financing

More from Business

Glenmark Chief On IGI’s Landmark Trispecific Deal: Strong Data Excited AbbVie

 

Glenmark’s managing director talks about IGI’s billion dollar-plus deal with AbbVie, ISB-2001’s striking data, the BEAT platform, other "exciting" pipeline assets and the "blood, sweat and tears" to get to this stage.

AbbVie Licenses IGI’s ISB 2001 In Second Myeloma Trispecific Deal For 2025

 

IGI CEO Cyril Konto said in an interview that his company picked AbbVie for its agility, drug development acumen and expertise in areas like intellectual property and legal affairs.

Merck & Co. Remains In The BD Game After Verona Takeout

 

CEO Rob Davis said the company is in pursuit of more deals as it looks to close the revenue gap looming from the loss of Keytruda in 2028.